New SOS1 inhibitors divulged in Sichuan Huiyu patent

June 15, 2026

Sichuan Huiyu Pharmaceuticals Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have patented new Son of sevenless homolog 1 (SOS1) inhibitors potentially useful for the treatment of cancer and Noonan syndrome.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for July 6, 2026.

CINP 2026: Prenatal and adolescent stress shape brain vulnerability

BioWorld Science

Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...

Ontrack Therapeutics divulges compounds for neurodegenerative diseases

BioWorld Science

Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

Neuracle eyes Shanghai IPO as global BCI funding surges

BioWorld

Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...